安立生坦对合并肺动脉高压的慢性阻塞性肺疾病的疗效观察

Effects of ambrisentan on chronic obstructive pulmonary diseases complicated with pulmonary arterial hypertension

目的:观察安立生坦对合并肺动脉高压(PH)的慢性阻塞性肺疾病(COPD)的疗效。方法:将42例合并PH的COPD患者分为安立生坦组(组A)和对照组(组B),每组21例,组A在常规治疗的基础上加用安立生坦,5 mg,口服,每天一次,连续治疗6个月,记录治疗前后第1秒用力呼气容积(forced expiratory volume in 1 second,FEV1)、用力肺活量(forced vital capacity,FVC)、动脉血气氧分压(PO2)、二氧化碳分压(PCO2)、谷草转氨酶(AST)、谷丙转氨酶(ALT)、N端脑钠肽前体(NT-ProBNP)、肺动脉收缩压(PASP)。结果:治疗后A组的FEV1、FVC、PO2较B组明显升高,PCO2、NT-Pro-BNP和PASP较组B明显降低,2组的AST、ALT无显著性差异。结论:安立生坦能显著改善合并PH的COPD患者的通气功能、心功能及肺动脉压力。

OBJECTIVE To observe the effect of the ambrisentan on chronic obstructive pulmonary diseases（COPD） complicated with pulmonary arterial hypertension（PH）.METHODS 42 Patients suffering from COPD complicated with PH were randomly divided into two groups：ambrisentan group（group A） and control group（group B）.Each group had 21 patients.Patients in group A were treated with ambrisentan（5 mg,po,qd × 6 m） on the basis of traditional therapy.Group B were only accepted traditional treatment.FEV1,FVC,PO2,PCO2,AST,ALT,NT-Pro-BNP and PASP were measured and compared before and after treatment.RESULTS FEV1,FVC and PO2 in group A were increased significantly than those in group B after six months.NT-Pro-BNP,PASP and PCO2 were decreased significantly in group A than those in group B.AST and ALT had no statistically difference in two groups.CONCLUSION Ambrisentan is effective for patients suffering from COPD complicated with PH.